Skip to main content

Hormone Treatment and Alzheimer’s Disease: Déjà Vu or Confused All Over Again?

The Original Article was published on 03 August 2021

This is a preview of subscription content, access via your institution.

Notes

  1. With the possible exception of undergoing surgical or chemical menopause at a younger age without estrogen treatment up to the natural age of menopause at 51 years. [14]

References

  1. Caldwell BM, Watson RI. An evaluation of psychologic effects of sex hormone administration in aged women. I. Results of therapy after six months. J Gerontol. 1952;7:228–44.

    CAS  Article  Google Scholar 

  2. Caldwell BM. An evaluation of psychological effects of sex hormone administration in aged women. II. Results of therapy after 18 months. J Gerontol. 1954;9(2):168–74.

    CAS  Article  Google Scholar 

  3. Sherwin BB. Estrogenic effects on memory in women. Ann N Y Acad Sci. 1994;743:213–30.

    CAS  Article  Google Scholar 

  4. Kantor HI, Michael CM, Shore E. Estrogen for older women. Am J Obstet Gynecol. 1973;4:31–47.

    Google Scholar 

  5. Hogervorst E, Yaffe K, Richards M, et al. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev. 2002;3:CD003122.

    Google Scholar 

  6. Ohkura T, Isse K, Akazawa K, et al. Low-dose estrogen replacement therapy for Alzheimer disease in women. Menopause. 1994;1:125–30.

    Google Scholar 

  7. Asthana S, Craft S, Baker LD, et al. Cognitive and neuroedocrine response to transdermal estrogen in postmenopausal women with AD: results of a placebo-controlled, double-blind pilot study. Psychoneuroendocrinology. 1999;24:657–77.

    CAS  Article  Google Scholar 

  8. Hogervorst E, Williams J, Combrinck M, David Smith A. Measuring serum oestradiol in women with Alzheimer's disease: the importance of the sensitivity of the assay method. Eur J Endocrinol. 2003;148(1):67-72. https://doi.org/10.1530/eje.0.1480067. PMID: 12534359

    CAS  Article  Google Scholar 

  9. Barrett-Connor E. Rethinking estrogen and the brain. JAGS. 1998;46:918–20.

    CAS  Article  Google Scholar 

  10. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. JAMA. 2003;289:2651–62.

    CAS  Article  Google Scholar 

  11. Cardinali CA, Akamine-Martins Y, Torrão AS. Use of hormone therapy in postmenopausal women with Alzheimer’s disease: a systematic review. Drugs Aging. 2021;38(9). https://doi.org/10.1007/s40266-021-00878-y

  12. Hogervorst E, Yaffe K, Richards M, et al. HRT to maintain cognitive function in women with dementia. Cochrane Database Syst Rev. 2009;21(1):CD003799.

    Google Scholar 

  13. Hogervorst E, Boshuisen M, Riedel WJ, et al. The effect of hormone replacement therapy on cognitive function in elderly women. Psychoneuroendocrinology. 1999;24:43–68.

    CAS  Article  Google Scholar 

  14. Hogervorst E, Henderson VW, Gibbs RB, et al. Hormones, cognition and dementia. Cambridge: Cambridge University Press; 2019.

    Google Scholar 

  15. McEwen BS, Woolley CS. Estradiol and progestrone regulate neuronal structure and synaptic connectivity in adult as well as developing brain. Exp Gerontol. 1994;29(3–4):431–6.

    CAS  Article  Google Scholar 

  16. Petitti DB, Buckwalter GJ, Crooks VC, et al. Prevalence of dementia in users of hormone replacement therapy as defined by prescription data. J Gerontol A Biol Sci Med Sci. 2002;57(8):M532–8.

    Article  Google Scholar 

  17. Hogervorst E, Williams J, Budge M, et al. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000;101(3):485–512.

    CAS  Article  Google Scholar 

  18. Matthews KA, Kuller LH, Wing RR, et al. Prior to use of estrogen replacement therapy: are users healthier than nonusers? Am J Epidemiol. 1996;143(10):971–8.

    CAS  Article  Google Scholar 

  19. Livingston G, Huntley J, Somerlad A, et al. Dementia prevention, intervention and care. Lancet. 2020;396(10248):413–46.

    Article  Google Scholar 

  20. Irving K, Hogervorst E, Oliveira D, et al. New developments in dementia prevention research. New York: Routledge; 2018.

    Book  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Eef Hogervorst.

Ethics declarations

Funding

Eef Hogervorst received funding from the Alzheimer’s Association, Newton Trust and British Council for her work on (phyto)oestrogens. No funding was specifically received for the publication of this commentary.

Conflict of interest

Eef Hogervorst has no conflicts of interest that are directly relevant to the content of this commentary.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Code avail ability

Not applicable.

Author contributions

EH is the sole author of this commentary.

Additional information

This comment refers to the article available at https://doi.org/10.1007/s40266-021-00878-y.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hogervorst, E. Hormone Treatment and Alzheimer’s Disease: Déjà Vu or Confused All Over Again?. Drugs Aging 38, 793–795 (2021). https://doi.org/10.1007/s40266-021-00887-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-021-00887-x